Peter M. Carlson was appointed Chief Financial Officer in March 2020, after joining MiMedx in December 2019 as Executive Vice President of Finance. Previously, Mr. Carlson served as Chief Operating Officer at Brighthouse Financial, Inc., where he helped establish the $200 billion (assets) U.S. life and annuity insurance company as a separate entity following its August 2017 spin-off from MetLife, Inc. He was the Chief Accounting Officer at MetLife, Inc. for eight years where his global responsibilities included accounting, financial planning, tax, and investment finance. Prior to joining MetLife in 2009, Carlson was the Corporate Controller at Wachovia Corporation. He currently serves as a director of White Mountains Insurance Company (NYSE: WTM). Mr. Carlson holds a Bachelor of Science from Wake Forest University and is a trustee of the university. He is licensed as a certified public accountant in North Carolina and New York.
Mr. Graves joined MiMedx in July 2018 and brings more than 20 years of pharmaceutical and biotech industry experience to the Company, ranging from compliance and sales management to government affairs. He most recently was the U.S. leader for the global Patient Experience & Value function in the neurology division of UCB, Inc., a biopharmaceutical company. From 2011 to 2015, he was UCB’s Deputy Compliance Officer involved in all aspects of compliance including the implementation and management of the company’s corporate integrity agreement. Prior to that, Graves was Senior Director in the Office of Ethics and Compliance for the Pharmaceutical Products Division of Abbott Laboratories, as well as Deputy Ethics & Compliance Officer for Takeda Pharmaceuticals North America, Inc. and TAP Pharmaceutical Products, Inc. Prior to his pharmaceutical and biotech career, he practiced labor and employment law.
Mr. Graves holds a B.A. in Criminology and Law, and a J.D. from the University of Florida as well as an MBA from the University of Chicago Booth School of Business.
Mr. Hulse joined MiMedx in December 2019, and brings to MiMedx more than twenty years’ experience in large law firms and life sciences organizations, with significant legal, risk management, compliance and operational expertise.
Prior to joining the Company, Mr. Hulse was a member of Dykema, a national law firm, since 2017. Prior thereto, he was with Acelity, LP, Inc. (formerly Kinetic Concepts, Inc.) from 2008-2017 in a variety of roles of increasing responsibility. In his last role with Acelity, he served as Chief Compliance Officer and Senior Vice President for Enterprise Risk Management, Quality, and Regulatory. Prior to that, he served as Division General Counsel and Associate General Counsel for litigation matters. Mr. Hulse holds a Bachelor of Arts from Angelo State University and a Juris Doctorate from the Baylor University School of Law.
Dr. Koob is the Chief Scientific Officer of MiMedx. He is the senior executive responsible for the overall research direction and oversight of the Company’s product and tissue offerings. Dr. Koob is the inventor on the patents related to the Company’s CollaFix™ technology that are the basis of the Company’s license agreement with Shriners Hospitals for Children and the University of South Florida. MiMedx was founded around the collagen technology developed by Dr. Koob.
Prior to MiMedx, Dr. Koob was Section Chief of Skeletal Biology at Shriners Hospital for Children in Tampa, Florida. During the fourteen years he held this position, Dr. Koob developed and patented the core technology for what would become the MiMedx CollaFix™ technology platform. Prior to his tenure with Shriners, Dr. Koob held various research appointments at institutions such as the Department of Biology at Boston University, Department of Biological Chemistry at Harvard Medical School, Department of Biology at the University of New Mexico, Department of Anatomy at the University of New Mexico School of Medicine, Orthopaedic Biomechanics Laboratory at Beth Israel Hospital, and Mount Desert Island Biological Laboratory.
Dr. Koob has published over 125 biomedical and biological articles and 12 book chapters, and he is listed as an inventor on over 40 issued and pending patents.
Dr. Koob received his Ph.D. in Biochemistry from Washington University School of Medicine in St. Louis, Missouri. He completed four years of post-doctoral training at Harvard Medical School and four years of specialty training in the Laboratory of Skeletal Disorders, Department of Orthopaedics at Children’s Hospital Medical Center in Boston.
Dr. Mason was named the Company’s Chief Medical Officer in December 2018. Dr. Mason joined MiMedx in June 2014, in the position of Vice President of Medical Affairs for Clinical Programs. Dr. Mason is a Board Certified Internist, board eligible in Rheumatology and Infectious Diseases, whose experience includes a 27-year pharmaceutical and medical device industry career, with increasing levels of responsibility. His experience covers multiple therapeutic areas and includes management of Clinical Development and Medical Affairs groups; Regulatory Affairs including QA; Public Affairs, Public Policy and Public Relations. Dr. Mason has extensive experience in all phases of drug development including preclinical, regulatory and clinical trials from Phases I through IV. His vast experience includes handling IND filings, protocol writing, more than ten successful BLA and NDA submissions, multiple successful 510(k) and de novo device clearances, and a similar number of drug and device product launches.
Before joining MiMedx, Dr. Mason previously served as Senior Vice President and Chief Medical Officer of Given Imaging where he led clinical trials, regulatory affairs and medical marketing initiatives. Before joining Given, Dr. Mason served with UCB Pharma as the company’s Vice President, Clinical Development and Global Head of Inflammation Clinical Research. In this role, Dr. Mason led the U.S. and U.K. teams in support of the regulatory pathways for the company’s portfolio of anti-inflammatory drugs. Dr. Mason also served with AVI BioPharma as its Senior Vice President of Clinical Development and Regulatory Affairs where he led drug development efforts including clinical programs in multiple therapeutic areas.
After medical school, Dr. Mason pursued a 15 year career in medical practice in both academic and private practice settings. During this time, Dr. Mason was a practicing physician in internal medicine, infectious diseases and rheumatology. Following his tenure in medical practice, Dr. Mason began his pharmaceutical and medical device industry career by joining Ciba-Geigy Pharmaceuticals in the capacity of Director, Clinical Research and Executive Director, Medical Affairs.
Dr. Mason has authored more than 15 manuscripts on clinical studies that have been published in peer-reviewed literature. He has authored a textbook article and a number of clinical abstracts that have been published in peer-reviewed journals.
Dr. Mason received his M.D. from Duke University Medical School. He earned a BA in Chemistry from Williams College. He completed an internship and fellowship in Rheumatology at Duke University Hospital and completed his residency in Internal Medicine at the University of Michigan Medical Center. Dr. Mason has also served as a Research Associate and USPHS SA Surgeon (Lt. Comm.) at NIH, NIAID, Laboratory of Viral Diseases, Bethesda, Maryland.
Dr. Robert B. Stein, M.D., Ph.D. joined MiMedx in August 2020 as Executive Vice President, Research and Development. After completing his Bachelors of Science with honors, earning a double major in both biology and chemistry at Indiana University, Dr. Stein received his M.D. and Ph.D. in Physiology and Pharmacology and completed his internship, residency and Board Certification in Anatomic and Clinical Pathology, all at Duke University. Following residency, Dr. Stein worked at Merck, with contributions to Cozaar, Sustiva, and Gardasil. He was then recruited as the first head of Research and Development for Ligand Pharmaceuticals, with responsibility for building the Research and Development organization and programs targeting various nuclear hormone receptors. This work led to eight pharmaceutical partnerships and six marketed medicines, including two SERMs (Fablyn and Viviant), three novel retinoids (Panretin, Targetin gel and capsules), and Promacta, the small molecule Thrombopoietin mimetic.
After six years at Ligand, he became Executive Vice President, Research and Pre-clinical Development for DuPont-Merck and DuPont pharmaceuticals, leading to the registration of Sustiva and Innohep and the discovery and advancement of blockbuster Eliquis, subsequently registered by Bristol Myers Squibb Company. Following the acquisition of DuPont by Bristol Myers Squibb, Dr. Stein joined Incyte Pharmaceuticals as President, R&D and Chief Scientific Officer, spearheading the transition from genomics to drug discovery and development. Following Incyte, Dr. Stein became President of Roche Palo Alto LLC, where he built Roche's Translational Medicine capabilities, served on the Global Early Development Committee, Global Biologics Steering Committee, and Joint Roche-Genentech Steering Committee. Dr. Stein then joined Kinemed, a translational medicine company as Chief Executive Officer.
Following Kinemed, Dr. Stein served as President, R&D, for Agenus, an immuno-oncology company, with responsibility for the development of their R&D organization, and the advancement of four checkpoint modulatory antibodies and a personalized neo-epitope-directed cancer vaccine to Phase 1 trials. He also led the generation of a best-in-class TCR discovery and optimization effort. He served as a full time Senior Advisor, R&D, to Agenus and AgenTus from March 2017 to October 2019. During this time, Agenus advanced 13 monoclonal antibodies into the clinic and formed significant partnerships with Incyte, Merck, UCB, and Gilead. The two most advanced Agenus products, AGEN2034 (PD-1 antagonist monoclonal antibody) and AGEN1884 (CTLA-4 antagonist monoclonal antibody) are on track for potential BLA submission in 2020.
Dr. Stein is deeply experienced in the lab, including in the areas of molecular and cellular biology, biochemistry, enzymology, animal pharmacology, virology, drug metabolism, and safety assessment. He also has extensive experience in Translational Medicine and Early Clinical Development. He has led groups of over 1,000 scientists and physicians for over 15 years, supervising work in all the major therapeutic areas. In addition, Dr. Stein serves on the board of directors for a number of private and public company boards, and acts as an advisor to a multiple clients and academic institutions.
Jack Howarth joined MiMedx in December 2020. Prior to joining the Company, Mr. Howarth served as Vice President, Corporate Affairs at Antares Pharmaceuticals. Previously, he served as head of corporate and investor relations at King Pharmaceuticals until the acquisition by Pfizer; and held senior leadership positions in Corporate Affairs at Alpharma, KOS Pharmaceuticals and Elan Corporation. Mr. Howarth also held senior positions in finance and corporate development during his nearly two decades at Warner Lambert Company, until that company was acquired by Pfizer in June of 2000.
Mr. Howarth received his B.S. degree in Accounting from Boston College and M.B.A. in Finance from Seton Hall University. He also earned baccalaureate and post-graduate certificates from the Rutgers Institute of Management and Labor Relations and The Wharton School at the University of Pennsylvania.
Stan Micek joined MiMedx in December, 2019. Prior to joining the Company, Mr. Micek served as the Vice President and Chief Commercial Officer for M2Gen, Corp. where he was responsible for all commercialization activities of the company including business development, strategic alliances, field sales and corporate communications.
From 2014 to 2018, Mr. Micek served as the Director, Oncology Commercialization at The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute (OSUCCC – James) and Director of Licensing for The Ohio State University’s (OSU) Technology Commercialization Office. Prior to joining OSU, he held executive roles within two mid-sized pharmaceutical companies leading their corporate and business development functions, specifically in- and out-licensing, acquisitions, and divestitures. Mr. Micek also brings nineteen years of experience from Abbott Laboratories, where he held positions of increasing responsibility in several functional areas, including national account sales, marketing, business development and licensing, engineering and international manufacturing / operations.
Mr. Micek earned his BS in Chemical Engineering from the Illinois Institute of Technology in Chicago and his MBA in Marketing and International Management from Northwestern University’s Kellogg Graduate School of Management in Evanston, IL.
Scott Turner, has served as Senior Vice President, Operations and Procurement since April 2017. Mr. Turner oversees supply chain operations including donor recovery services, planning, procurement, processing, and facilities. Mr. Turner joined the Company in April 2016 as Vice President, Procurement. Prior to joining MiMedx, Mr. Turner served as a Director with Alvarez & Marsal, North America, LLC, in their Corporate Performance Improvement group from October 2015 until March 2016. Prior thereto, Mr. Turner served as Vice President, Supply Chain, with Larson-Juhl, a Berkshire Hathaway company, from June 2013 until September 2015. Additionally, Mr. Turner’s has more than 20 years of Supply Chain and Procurement leadership in life sciences at Shionogi and Johnson & Johnson, spanning the consumer, medical device, and pharmaceutical sectors domestically and internationally. Mr. Turner holds a Bachelor of Science in Commerce & Engineering from Drexel University and a President / Key Executives MBA from Pepperdine University.
Dr. Brown joined SpineMedica LLC, an early-stage predecessor company to MiMedx, in 2005. She initially served as the Director of Project Management and Senior Engineer for SpineMedica, and later served as its Director of Research and Development and as Vice President of Operations. In those roles, she was instrumental in the development and launch of the Company’s HydroFix® technology. Since the Company’s inception, Dr. Brown was been leading the Company’s product development efforts, including growing and managing the intellectual property portfolio. Following the combination of SpineMedica with MiMedx, Inc. in 2007, Dr. Brown has served as the Company’s senior executive responsible for Product Development. In April 2013, Dr. Brown was named Vice President of Product Development, Regulatory Affairs and Quality Assurance.
Dr. Brown has over twenty years of experience leading teams to produce innovative and impactful products. She has worked at companies ranging in size from 12 employees to 120,000, and has an impressive track record for integrating customer needs with company goals.
Before joining SpineMedica, Dr. Brown worked as Project Manager and Staff Engineer at SaluMedica, LLC, a medical device company pioneering the development of devices to replace soft tissue throughout the body. While a graduate student at the Georgia Institute of Technology where her research focused on the durability of orthopedic implants, Dr. Brown also worked with SaluMedica, as well as Oak Ridge National Laboratory and Advanced Tissue Sciences. Dr. Brown designed and fabricated mechanical testing systems to evaluate the durability of cartilage and cartilage prostheses.
Dr. Brown has also worked at Centerpulse (formerly Sulzer Medica) in Winterthur, Switzerland as a Research Engineer where she investigated xenograph amd tissue engineering options for articular cartilage repair and treatment. Before Centerpulse, Dr. Brown worked as a Product/Process Engineer at Hewlett-Packard.
Dr. Brown holds a Ph.D. and M.S. from the Georgia Institute of Technology, where she was a National Science Foundation Graduate Research Fellow, and a B.S. in Mechanical Engineering from the Massachusetts Institute of Technology.
Mr. Burrows joined MiMedx Group in April 2011 as Vice President of Wound Care to lead the marketing of the Company’s wound care offerings and other exciting products and tissues. He assumed the role Of Vice President of Global Marketing in August 2011 to focus on expanding the Company’s presence in the regenerative tissue market. In October 2012, Mr. Burrows was appointed to the position of Vice President of Corporate Strategy. He has brought to MiMedx over 20 years of experience and expertise in developing and implementing sales and marketing plans that have created prolific growth for numerous medical devices and pharmaceuticals. In March 2014, Mr. Burrows was named Vice President of Clinical and Scientific Liaison.
Mr. Burrows has held positions with notable companies like Johnson & Johnson, Smith & Nephew, W.L. Gore and CryoLife. In Mr. Burrow’s 20-year career, he has amassed a track record for successfully developing and implementing strategic and tactical marketing plans to launch and grow medical devices, human tissue, and pharmaceuticals in the areas of tissue engineering; regenerative medicine; wound closure and healing; growth factor therapy; cardiothoracic, vascular, endovascular surgery; diabetes; women’s health; anesthesia; heart disease; biologics; and bio-active therapeutics.
Mr. Burrows’ most recent role prior to joining MiMedx Group was with CryoLife, Inc., where he served as Director of Marketing and had responsibility for development and execution of marketing plans for allograft tissues for uses in aortic, pulmonary and vascular procedures. Before his tenure with CryoLife, he was Director of Sales & Marketing for Histogen Aesthetics, a startup biotechnology company in the regenerative medicine market. Prior thereto, he was Marketing Director for W.L. Gore from 2006 to 2008 and had responsibility for leading their global marketing efforts in the Abdominal, Aortic and Aneurysm (AAA) endovascular market segment.
From 2001 to 2006, Mr. Burrows served with J&J Wound Management Company, a division of ETHICON, as Director of Professional Education from 2004 to 2006 and as Sr. Product Director from 2001 to 2004. With J&J, he successfully revitalized and re-launched their brand in the highly differentiated and competitive advanced wound care market and directed their formal education programs to drive scientific and clinical utilization rationale. From 1999 to 2000, Mr. Burrows served as Vice President of Adient and directed its account teams serving key accounts such as Bristol-Myers Squibb and Ortho-McNeil. He served as Marketing Manager, Acute Care with Smith & Nephew from 1997 to 1999 focusing on their acute care products and supporting the launch of the Company’s novel biotechnology and advanced wound care products. In 1991, Mr. Burrows began his career with Advanced Tissue Sciences, where he held numerous marketing and business development roles.
Mr. Burrows holds degrees in Marketing from Point Loma Nazarene University and an MBA in Marketing & Advertising from University of La Verne. Mr. Burrows received his EMT from Saint Michael’s Medical Center.
Mr. Spencer is the co-founder of Surgical Biologics, a leading processor of amnion tissue for use in a variety of surgical implants. Since the founding of Surgical Biologics in 2006, he led the development of the proprietary PURION® Process, which processes human amniotic membrane to produce a safe, effective and minimally manipulated implant for homologous use. He has been a pioneer in the development of the latest advances in processing amniotic membrane tissue. MiMedx® acquired Surgical Biologics in January 2011, and Mr. Spencer served as the Company’s Director of Product Development until March 2013, when he assumed the role of Vice President of Clinical Innovation.
Mr. Spencer has been in the bioimplant industry since its infancy, with over 23 years of experience. He is an industry expert in the development of new products and new surgical treatments using bioimplant materials. Throughout his career, Mr. Spencer has made significant contributions to the development of a wide range of products which are now considered the standard of care for certain surgical procedures.
Before founding Surgical Biologics, he was Product Manager Bone Biopsy Division at InterV Medical Device Technologies. Prior to InterV, Mr. Spencer was Product Manager Regenerative Products at Tutogen Medical, where he designed products used in spinal and dental surgeries. Before joining Tutogen, he was with Regeneration Technologies, where Mr. Spencer created products that are used in spinal, sports medicine and orthopedic surgeries. Earlier in his career, Mr. Spencer worked for Johns Hopkins University as a researcher.
Mr. Spencer earned a Bachelors of Science degree in Health Science from Grand Valley State University.